Plasma Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Cardiovascular Events in Patients with Chronic Kidney Disease

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Hasegawa, Midori ^a   Ishii, Junichi ^a   Kitagawa, Fumihiko ^b   Takahashi, Hiroshi ^c   Sugiyama, Kazuhiro ^a   Tada, Masashi ^a   Kanayama, Kyoko ^a   Takahashi, Kazuo ^a   Hayashi, Hiroki ^a   Koide, Shigehisa ^a   Nakai, Shigeru ^a   Ozaki, Yukio ^a   Yuzawa, Yukio ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ADULT; AGED; AORTA DISSECTION; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; KAPLAN MEIER METHOD; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIPOCALIN-2; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; ROC CURVE;

EID: 84962921747     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/8761475     Document Type: Article

References (34)

1. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, "Clinical epidemiology of cardiovascular disease in chronic renal disease, " American Journal of Kidney Diseases, vol. 32, no. 5, supplement 3, pp. S112-S119, 1998.
2. D. S. Keith, G. A. Nichols, C. M. Gullion, J. B. Brown, and D. H. Smith, "Longitudinal follow-up and outcomes among a population with chronic kidney disease in a largemanaged care organization, " Archives of Internal Medicine, vol. 164, no. 6, pp. 659-663, 2004.
3. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-Y. Hsu, "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, " The New England Journal of Medicine, vol. 351, no. 13, pp. 1296-1370, 2004.
4. T. Ninomiya, Y. Kiyohara, M. Kubo et al., "Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study, " Kidney International, vol. 68, no. 1, pp. 228-236, 2005.
5. C. Ronco, M. Cicoira, and P. A. McCullough, "Cardiorenal syndrome type 1: Pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure, " Journal of the American College of Cardiology, vol. 60, no. 12, pp. 1031-1042, 2012.
6. R. Tagore, L. H. Ling, H. Yang, H.-Y. Daw, Y.-H. Chan, and S. K. Sethi, "Natriuretic peptides in chronic kidney disease, " Clinical Journal of the American Society of Nephrology, vol. 3, no. 6, pp. 1644-1651, 2008.
7. M. J. Sarnak, R. Katz, A. Newman et al., "Association of urinary injury biomarkers with mortality and cardiovascular events, " Journal of the American Society of Nephrology, vol. 25, no. 7, pp. 1545-1553, 2014.
8. M. Kuoppamäki, M. Salminen, T. Vahlberg, K. Irjala, S.-L. Kivelä, and I. Räihä, "High sensitive C-reactive protein (hsCRP), cardiovascular events and mortality in the aged: A prospective 9-year follow-up study, " Archives of Gerontology and Geriatrics, vol. 60, no. 1, pp. 112-117, 2015.
9. S. Y. Xu, M. Carlson, A. Engström, R. Garcia, C. G. B. Peterson, and P. Venge, "Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils, " Scandinavian Journal of Clinical and Laboratory Investigation, vol. 54, no. 5, pp. 365-376, 1994.
10. J. Mishra, M. A. Qing, A. Prada et al., "Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury, " Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2534-2543, 2003.
11. K. Mori, H. T. Lee, D. Rapoport et al., "Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury, " Journal of Clinical Investigation, vol. 115, no. 3, pp. 610-621, 2005.
12. J. Mishra, C. Dent, R. Tarabishi et al., "Neutrophil gelatinaseassociated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery, " The Lancet, vol. 365, no. 9466, pp. 1231-1238, 2005.
13. A. Clerico, C. Galli, A. Fortunato, and C. Ronco, "Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: A review of the laboratory characteristics and clinical evidences, " Clinical Chemistry and LaboratoryMedicine, vol. 50, no. 9, pp. 1505-1517, 2012.
14. D. N. Cruz, S. Gaiao, A. Maisel, C. Ronco, and P. Devarajan, "Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: A systematic review, " Clinical Chemistry and Laboratory Medicine, vol. 50, no. 9, pp. 1533-1545, 2012.
15. K. Makris, D. Rizos, N. Kafkas, and A. Haliassos, "Neurophil gelatinase-associated lipocalin as a newbiomarker in laboratory medicine, " Clinical Chemistry and LaboratoryMedicine, vol. 50, no. 9, pp. 1519-1532, 2012.
16. S. Matsuo, E. Imai, M. Horio et al., "Revised equations for estimated GFR from serum creatinine in Japan, " American Journal of Kidney Diseases, vol. 53, no. 6, pp. 982-992, 2009.
17. J. Kanda, K. Mori, H. Kawabata et al., "An AKI biomarker lipocalin 2 in the blood derives from the kidney in renal injury but fromneutrophils in normal and infected conditions, " Clinical and Experimental Nephrology, vol. 19, no. 1, pp. 99-106, 2015.
18. T. Kuwabara, K. Mori, M. Mukoyama et al., "Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons, " Kidney International, vol. 75, no. 3, pp. 285-294, 2009.
19. D. Bolignano, V. Donato, G. Coppolino et al., "Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage, " American Journal of Kidney Diseases, vol. 52, no. 3, pp. 595-605, 2008.
20. G. P. Otto, J. Hurtado-Oliveros, H. Y. Chung et al., "Plasma neutrophil gelatinase-associated lipocalin is primarily related to inflammation during sepsis: A translational approach, " PLoS ONE, vol. 10, no. 4, Article IDe0124429, 2015.
21. D. Bolignano, G. Coppolino, V. Donato, A. Lacquaniti, C. Bono, and M. Buemi, "Neutrophil gelatinase-associated lipocalin (NGAL): A new piece of the anemia puzzle?" Medical Science Monitor, vol. 16, no. 6, pp. RA131-RA135, 2010.
22. A. Yndestad, L. Landrø, T. Ueland et al., "Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure, " European Heart Journal, vol. 30, no. 10, pp. 1229-1236, 2009.
23. M. Folkesson, M. Kazi, C. Zhu et al., "Presence ofNGAL/MMP-9 complexes in human abdominal aortic aneurysms, " Thrombosis and Haemostasis, vol. 98, no. 2, pp. 427-433, 2007.
24. A.-L. Hemdahl, A. Gabrielsen, C. Zhu et al., "Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 1, pp. 136-142, 2006.
25. D. Bolignano, G. Basile, P. Parisi, G. Coppolino, G. Nicocia, and M. Buemi, "Increased plasma neutrophil gelatinase-associated lipocalin levels predictmortality in elderly patientswith chronic heart failure, " Rejuvenation Research, vol. 12, no. 1, pp. 7-14, 2009.
26. K. Shrestha, A. G. Borowski, R. W. Troughton, J. D. Thomas, A. L. Klein, and W. H. W. Tang, "Renal dysfunction is a stronger determinant of systemic neutrophil gelatinaseassociated lipocalin levels than myocardial dysfunction in systolic heart failure, " Journal of Cardiac Failure, vol. 17, no. 6, pp. 472-478, 2011.
27. S. Lindberg, S. H. Pedersen, R. Mogelvang et al., "Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with STsegment elevation myocardial infarction treated with primary percutaneous coronary intervention, " Journal of the American College of Cardiology, vol. 60, no. 4, pp. 339-345, 2012.
28. P. Falke, A. M. Elneihoum, and K. Ohlsson, "Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia, " Cerebrovascular Diseases, vol. 10, no. 2, pp. 97-101, 2000.
29. L. B. Daniels, E. Barrett-Connor, P. Clopton, G. A. Laughlin, J. H. Ix, and A. S. Maisel, "Plasma neutrophil gelatinaseassociated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: the Rancho Bernardo Study, " Journal of the American College of Cardiology, vol. 59, no. 12, pp. 1101-1109, 2012.
30. S. H. Nymo, T. Ueland, E. T. Askevold et al., "The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA, " Journal of Internal Medicine, vol. 271, no. 5, pp. 436-443, 2012.
31. M. McNairy, N. Gardetto, P. Clopton et al., "Stability of Btype natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide, " American Heart Journal, vol. 143, no. 3, pp. 406-411, 2002.
32. A. Maisel, "B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next?" Circulation, vol. 105, no. 20, pp. 2328-2331, 2002.
33. Y. Takami, T. Horio, Y. Iwashima et al., "Diagnostic and prognostic value of plasma brain natriuretic peptide in nondialysis-dependent CRF, " American Journal of Kidney Diseases, vol. 44, no. 3, pp. 420-428, 2004.
34. M. Hasegawa, J. Ishii, F. Kitagawa et al., "Urinary neutrophil gelatinase-associated lipocalin as a predictor of cardiovascular events in patients with chronic kidney disease, " Heart and Vessels, vol. 30, pp. 81-88, 2015.